SCHEMBL1749037

SCHEMBL1749037

Cc1ccc(S(=O)(=O)n2ccc3cc(F)cnc32)cc1

nearest known ligand 0.61

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.61
RAPGEF4 Q8WZA2 4/20 0.46
PKM P14618 1/20 0.45
CYP2C19 P33261 1/20 0.45
BRD4 O60885 2/20 0.43
ENPP3 O14638 1/20 0.42
ENPP1 P22413 1/20 0.42
POLB P06746 1/20 0.41
ALDH3A1 P30838 1/20 0.41
HTT P42858 1/20 0.41
NOD1 Q9Y239 1/20 0.41
FGFR4 P22455 1/20 0.40
HTR6 P50406 2/20 0.40
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40
ALDH1A1 P00352 1/20 0.38
TSHR P16473 1/20 0.38
LMNA P02545 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3500880 0.87 L3MBTL1 (0.66) L3MBTL1RAPGEF4PKMCYP2C19BRD4
SCHEMBL1960656 0.86 CYP2C19 (0.61) L3MBTL1RAPGEF4PKMCYP2C19POLB
SCHEMBL28383297 0.84 L3MBTL1 (0.61) L3MBTL1RAPGEF4PKMCYP2C19BRD4
SCHEMBL12696586 0.84 L3MBTL1 (0.61) L3MBTL1RAPGEF4PKMCYP2C19BRD4
SCHEMBL1713486 0.84 L3MBTL1 (0.61) L3MBTL1RAPGEF4PKMCYP2C19BRD4
SCHEMBL29605995 0.84 L3MBTL1 (0.61) L3MBTL1RAPGEF4PKMCYP2C19BRD4
SCHEMBL14487894 0.84 L3MBTL1 (0.61) L3MBTL1RAPGEF4PKMCYP2C19BRD4
SCHEMBL28325512 0.84 L3MBTL1 (0.61) L3MBTL1RAPGEF4PKMCYP2C19BRD4
SCHEMBL3500069 0.83 L3MBTL1 (0.57) L3MBTL1RAPGEF4PKMCYP2C19BRD4
SCHEMBL28555533 0.82 L3MBTL1 (0.56) L3MBTL1RAPGEF4PKMCYP2C19BRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180134730-A1 IMPROVED PROCESS FOR PREPARING BORYL 7-AZAINDOLE COMPOUNDS BOROPHARM INC (US) 2018-05-17 US claimed
WO-2025096463-A1 PLK4 MODULATORS VIBLIOME THERAPEUTICS, LLC (US) 2025-05-08 WO disclosed
CN-117362318-A PB2 inhibitor and preparation method and application thereof 西藏海思科制药有限公司 2024-01-09 CN disclosed
CN-115698011-B PB2 inhibitor and preparation method and application thereof 四川海思科制药有限公司 2023-10-20 CN disclosed
US-20230265107-A1 PB2 INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF SICHUAN HAISCO PHARMACEUTICAL CO., LTD. (CN) 2023-08-24 US disclosed
US-20230265107-A1 PB2 INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF SICHUAN HAISCO PHARMACEUTICAL CO., LTD. (CN) 2023-08-24 US disclosed
EP-4180434-A1 PB2 INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF Sichuan Haisco Pharmaceutical Co., Ltd. (CN) 2023-05-17 EP disclosed
CN-115698011-A PB2 inhibitor and preparation method and application thereof 四川海思科制药有限公司 2023-02-03 CN disclosed
US-11345700-B2 Methods of preparing inhibitors of influenza viruses replication VERTEX PHARMACEUTICALS INCORPORATED (US) 2022-05-31 US disclosed
EP-3851437-A2 METHODS OF PREPARING 1H-PYRROLO[2,3-B]PYRIDINE DERIVATES Vertex Pharmaceuticals Incorporated (US) 2021-07-21 EP disclosed
US-7968566-B2 Pyrrolo(2,3-b) pyridine derivatives, the preparation and the pharmaceutical use thereof in the form of kinase inhibitors AVENTIS PHARMA S.A. (FR) 2011-06-28 US disclosed
US-20100256141-A1 NOVEL BIS-AZAINDOLE DERIVATIVES, PREPARATION AND PHARMACEUTICAL USE THEREOF AS KINASE INHIBITORS AVENTIS PHARMA S.A. (FR) 2010-10-07 US disclosed
US-7786114-B2 Bis-azaindole derivatives, preparation and pharmaceutical use thereof as kinase inhibitors AVENTIS PHARMA S.A. (FR) 2010-08-31 US disclosed
US-20090233956-A1 NOVEL PYRROLO(2,3-b) PYRIDINE DERIVATIVES, THE PREPARATION AND THE PHARMACEUTICAL USE THEREOF IN THE FORM OF KINASE INHIBITORS AVENTIS PHARMA S.A. (FR) 2009-09-17 US disclosed
US-7528147-B2 Pyrrolo (2,3-b)pyridine derivatives, the preparation and the pharmaceutical use thereof in the form of kinase inhibitors AVENTIS PHARMA S.A. (FR) 2009-05-05 US disclosed
US-20080045561-A1 Novel Bis-Azaindole Derivatives, Preparation And Pharmaceutical Use Thereof As Kinase Inhibitors AVENTIS PHARMA S.A. (FR) 2008-02-21 US disclosed
EP-1799691-A1 NOVEL BIS-AZAINDOLE DERIVATIVES, PREPARATION AND PHARMACEUTICAL USE THEREOF AS KINASE INHIBITORS Aventis Pharma S.A. (FR) 2007-06-27 EP disclosed
US-20070093480-A1 Novel pyrrolo (2,3-b)pyridine derivatives, the preparation and the pharmaceutical use thereof in the form of kinase inhibitors AVENTIS PHARMA S.A. (FR) 2007-04-26 US disclosed
CN-1950083-A Novel pyrrolo (2,3-b)pyridine derivatives, the preparation and the pharmaceutical use thereof in the form of kinase inhibitors AVENTIS PHARMA SA (FR) 2007-04-18 CN disclosed
WO-2006037875-A1 NOVEL BIS-AZAINDOLE DERIVATIVES, PREPARATION AND PHARMACEUTICAL USE THEREOF AS KINASE INHIBITORS AVENTIS PHARMA S.A. (FR) 2006-04-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080045561-A1 Novel Bis-Azaindole Derivatives, Preparation And Pharmaceutical Use Thereof As Kinase Inhibitors BRSK2, KSR2, CDK2 L3MBTL1 4205/4885RAPGEF4 554/4885PKM 618/4885
US-20090233956-A1 NOVEL PYRROLO(2,3-b) PYRIDINE DERIVATIVES, THE PREPARATION AND THE PHARMACEUTICAL USE THEREOF IN THE FORM OF KINASE INHIBITORS MAP3K19, MAP4K2, MAP3K1 L3MBTL1 4601/4885RAPGEF4 690/4885PKM 282/4885
US-20100256141-A1 NOVEL BIS-AZAINDOLE DERIVATIVES, PREPARATION AND PHARMACEUTICAL USE THEREOF AS KINASE INHIBITORS BRSK2, KSR2, CDK2 L3MBTL1 4205/4885RAPGEF4 554/4885PKM 618/4885
US-20230265107-A1 PB2 INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF CYP11B2, WEE2, CYP11B1 L3MBTL1 1316/4885RAPGEF4 3693/4885PKM 1539/4885
US-20180134730-A1 IMPROVED PROCESS FOR PREPARING BORYL 7-AZAINDOLE COMPOUNDS AZI2, BCCIP, ADAR L3MBTL1 1781/4885RAPGEF4 315/4885PKM 3112/4885
US-11345700-B2 Methods of preparing inhibitors of influenza viruses replication ZC3HAV1, ZC3HAV1L, POLR2H L3MBTL1 3307/4885RAPGEF4 961/4885PKM 801/4885
US-20070093480-A1 Novel pyrrolo (2,3-b)pyridine derivatives, the preparation and the pharmaceutical use thereof in the form of kinase inhibitors MAP3K19, MAP4K2, MAP3K1 L3MBTL1 4601/4885RAPGEF4 690/4885PKM 282/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.